A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.

PharmacoEconomics
Kelly FustMarion Feuilly

Abstract

Carcinoid syndrome, a rare condition in patients with neuroendocrine tumours, characterised by flushing and diarrhoea, severely affects patients' quality of life. The current carcinoid syndrome standard of care includes somatostatin analogues, but some patients experience uncontrolled symptoms despite somatostatin analogue therapy. Telotristat ethyl is a novel treatment approved by the European Medicines Agency (EMA) and US FDA that significantly reduces bowel movement frequency in patients with uncontrolled carcinoid syndrome. We developed a model to evaluate the 5-year budget impact of introducing telotristat ethyl to standard care in Swedish patients with uncontrolled carcinoid syndrome. Treatment response in the 12-week phase III TELESTAR trial (NCT01677910) informed telotristat ethyl efficacy; subsequently, health states were captured by a Markov model using 4-week cycles. TELESTAR open-label extension data informed telotristat ethyl discontinuation. The number of treatment-eligible patients was estimated from literature reviews reporting the prevalence, incidence and mortality of carcinoid syndrome. A Swedish database study informed real-world costs related to carcinoid syndrome and carcinoid heart disease costs. Telotris...Continue Reading

References

Aug 1, 1995·Alimentary Pharmacology & Therapeutics·A G Harris, J S Redfern
Jun 20, 2001·The British Journal of Surgery·G WestbergK Caidahl
Jan 5, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P TomassettiR Corinaldesi
Jun 8, 2004·Endocrine Reviews·Gregory A KaltsasAshley B Grossman
Sep 16, 2004·Heart·David J Fox, Rajdeep S Khattar
Nov 14, 2007·European Journal of Gastroenterology & Hepatology·Dimitrios PapadogiasGregory Kaltsas
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Jul 4, 2009·Alimentary Pharmacology & Therapeutics·C ToumpanakisM E Caplin
Feb 8, 2011·The American Journal of Cardiology·Sanjeev BhattacharyyaJoseph Davar
Jan 21, 2012·Neuroendocrinology·Robert T JensenUNKNOWN Barcelona Consensus Conference participants
Jun 9, 2012·Journal of the National Comprehensive Cancer Network : JNCCN·Matthew H KulkeUNKNOWN National Comprehensive Cancer Networks
Jan 29, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Catharina M KorseOtto Visser
Aug 21, 2013·Orphanet Journal of Rare Diseases·Tim A KantersLeona Hakkaart
Feb 15, 2014·Orphanet Journal of Rare Diseases·Adam HutchingsKarolina Antonov
Jul 12, 2014·The New England Journal of Medicine·Martyn E CaplinUNKNOWN CLARINET Investigators
Apr 15, 2015·Neuroendocrinology·Simona Grozinsky-GlasbergDavid J Gross
Jan 20, 2016·Neuroendocrinology·G Delle FaveUNKNOWN Vienna Consensus Conference participants
Feb 16, 2016·World Journal of Gastroenterology : WJG·Michael S BroderMaureen P Neary
Feb 27, 2016·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Philippe RuszniewskiUNKNOWN SYMNET study group
May 24, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Aaron I VinikUNKNOWN ELECT Study Group *
Jul 28, 2016·Endocrine-related Cancer·Georgios K DimitriadisAshley Grossman
Dec 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeMarianne Pavel
Feb 17, 2017·Therapeutic Advances in Medical Oncology·Rachel P RiechelmannFrederico P Costa
Feb 28, 2017·The Lancet Oncology·Daniel M HalperinJames C Yao
Mar 11, 2017·Journal of the American College of Cardiology·Joseph DavarChristos Toumpanakis
Jan 14, 2018·Endocrine-related Cancer·Marianne PavelRocio Garcia-Carbonero
Aug 23, 2018·Clinics·Anezka C Rubin de Celis FerrariRachel P Riechelmann

❮ Previous
Next ❯

Citations

Aug 12, 2021·PharmacoEconomics·I-Wen PanYa-Chen Tina Shih

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.